Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

The expanded use of second-generation antiandrogens revolutionized the treatment landscape of progressed prostate cancer. However, resistances to these novel drugs are already the next obstacle to be solved. Various previous studies depicted an involvement of the enzyme AKR1C3 in the process of cast...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Kafka, Mona, Mayr, Fabian, Temml, Veronika, Möller, Gabriele, Adamski, Jerzy, Höfer, Julia, Schwaiger, Stefan, Heidegger, Isabel, Matuszczak, Barbara, Schuster, Daniela, Klocker, Helmut, Bektic, Jasmin, Stuppner, Hermann, Eder, Iris E.
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465893/
https://ncbi.nlm.nih.gov/pubmed/32731472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082092
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires